The Top 5 Biosimilar Articles for the Week of December 7

December 11, 2020

Here are the top 5 biosimilar articles for the week of December 7, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of December 7, 2020.

Number 5: A long-term, comparative, phase 3 trial of Celltrion’s CT-P10 vs the rituximab originator (Rituxan) has provided evidence of biosimilar value in follicular lymphoma.

Number 4: A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received a romiplostim biosimilar.

Number 3: The FDA clarified a number of concerns surrounding the appropriate procedures for industry to apply for interchangeability status.

Number 2: A survey by the World Health Organization (WHO) of 20 countries highlights the remaining regulatory challenges facing biosimilar adoption.

Number 1: To spur more biosimilar development and reduce anticompetitive practices, Boehringer Ingelheim argued the FDA could improve its interpretation of the term “strength” in the Biologics Price Competition and Innovation Act (BPCIA).

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News